If you have $10,000 to invest in the ASX today, but don't know which stocks to choose, take a look at my two top picks for the week.
Image source: Getty Images
NextDC Ltd (ASX: NXT)
Outperformance of shares in the technology sector this week has helped to offset some broader market weakness across the S&P/ASX 200 Index (ASX: XJO).
NextDC is one of those tech stocks driving momentum in the tech sector.
At the time of writing on Thursday morning, NextDC shares are changing hands at $17.235 per share, up 0.79% for the day. Over the past week, the share price has climbed 6.52% and over the past 6 months, it has risen 32.99%.
Analysts are positive that the stock has some more upside.
Earlier this month, Macquarie confirmed its outperform rating on the shares, saying that it expects the company's build-to-suit AI assets to support higher projected returns in FY26.
The broker also raised its 12-month target price to $22.30, up from $22.10 previously. That represents a potential upside of 29.4% from the current trading price.
According to TradingView data, some analysts expect an even higher upside. The data shows that 15 out of 17 analysts rate the stock as a buy or strong buy, and the maximum target price is $28.66 per share. This represents an upside as high as 66.3% for NextDC shares over the next 12 months.
Telix Pharmaceuticals Ltd (ASX: TLX)
Biopharmaceutical company Telix Pharmaceuticals is another ASX stock to watch this week. The share price crashed in July after the company was issued with a subpoena from the United States Securities and Exchange Commission (SEC). It suffered another setback from the US Food and Drug Administration (FDA) in late August which sent the share price tumbling yet again.
At the time of writing on Thursday morning, the shares are trading 2.84% lower for the day at $14.01. Thanks to the latest investor sell-off, the shares are 23.32% lower for the year.
Despite this disappointment, analysts are still positive on the stock and think that investors should be buying the dip.
Bell Potter recently confirmed its buy rating on the stock but reduced its target price to $23, down from $30 previously. According to the trading price at the time of writing, that still represents a robust potential upside of 64.2% for investors over the next 12 months.
Other analysts agree. According to TradingView data, 12 out of 13 analysts still hold a buy or strong buy rating on the shares. The maximum target price is as high as $35 per share, representing a potential upside of as much as 151.62% from the current trading price.
